Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
US 8,440,661 In forceTerm ends Nov 27, 2026 · From the USPTO record
20-year base term ended Jan 12, 2026
Jan 12, 2006
Nov 27, 2026
May 14, 2013
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 12, 2006, when the earliest non-provisional application in its chain was filed (this one was filed May 13, 2010) | Jan 12, 2026 | From the USPTO record |
| Continuity chain | Every parent in the chain resolved | no change | From the USPTO record |
| Patent term adjustment | +319 days, USPTO patent term adjustment record | Nov 27, 2026 | From the USPTO record |
| Terminal disclaimer cap | None on record | no cap applied | From the USPTO record |
| Patent term extension | None on file | no change | From the USPTO record |
| Fee events | 3 of 3 maintenance fees paid | In force | From the USPTO record |
| Computed term end | The steps above, in order | Nov 27, 2026 | From the USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.